Abstract
Use of non-overall survival (OS) endpoints in HTA assessments is limited by the difficulty in reliably proving long-term clinical and economic benefits. Using early breast cancer (EBC; stages 1 and 2) and multiple myeloma (MM; all stages) as examples, this research aims to identify the specific actions that must be taken to ensure that non-OS endpoints are fit-for-purpose for use in reimbursement decisions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
